Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Lyra Therapeutics stock

Learn how to easily invest in Lyra Therapeutics stock.

Lyra Therapeutics Inc is a biotechnology business based in the US. Lyra Therapeutics shares (LYRA) are listed on the NASDAQ and all prices are listed in US Dollars. Lyra Therapeutics employs 54 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Lyra Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LYRA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Lyra Therapeutics stock price (NASDAQ: LYRA)

Use our graph to track the performance of LYRA stocks over time.

Lyra Therapeutics shares at a glance

Information last updated 2022-01-23.
Latest market close$3.96
52-week range$3.30 - $16.50
50-day moving average $4.98
200-day moving average $7.34
Wall St. target price$22.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.85

Buy Lyra Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Stocks
$0
0%
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$0
$1 per month
$5
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Public
Stocks, ETFs, Cryptocurrency
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Lyra Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lyra Therapeutics price performance over time

Historical closes compared with the close of $3.96 from 2022-01-25

1 week (2022-01-18) -2.22%
1 month (2021-12-27) -14.66%
3 months (2021-10-27) -46.12%
6 months (2021-07-27) -36.94%
1 year (2021-01-27) -63.67%
2 years (2020-01-23) N/A
3 years (2019-01-23) N/A
5 years (2017-01-23) N/A

Lyra Therapeutics financials

Revenue TTM $14,000
Gross profit TTM $0
Return on assets TTM -29.85%
Return on equity TTM -57.64%
Profit margin 0%
Book value $3.63
Market capitalisation $49 million

TTM: trailing 12 months

Lyra Therapeutics share dividends

We're not expecting Lyra Therapeutics to pay a dividend over the next 12 months.

Lyra Therapeutics overview

Lyra Therapeutics, Inc. , a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018.

Frequently asked questions

What percentage of Lyra Therapeutics is owned by insiders or institutions?
Currently 1.412% of Lyra Therapeutics shares are held by insiders and 71.234% by institutions.
How many people work for Lyra Therapeutics?
Latest data suggests 54 work at Lyra Therapeutics.
When does the fiscal year end for Lyra Therapeutics?
Lyra Therapeutics's fiscal year ends in December.
Where is Lyra Therapeutics based?
Lyra Therapeutics's address is: 480 Arsenal Way, Watertown, MA, United States, 02472
What is Lyra Therapeutics's ISIN number?
Lyra Therapeutics's international securities identification number is: US55234L1052
What is Lyra Therapeutics's CUSIP number?
Lyra Therapeutics's Committee on Uniform Securities Identification Procedures number is: 55234L105

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site